Artemis Medicare Services Ltd. (IN:ARTEMISMED)
:ARTEMISMED
Top Page
Artemis Medicare Services Ltd.
(ARTEMISMED)
Select Model
Select Model
Rating:65Neutral
Price Target:
₹256.00
▼(-7.31% Downside)
Action:DowngradedDate:02/04/26
The score is primarily supported by strong financial performance (growth, improving margins, solid cash generation, and moderate leverage). This is offset by weak technicals showing a pronounced downtrend and negative momentum, and by a relatively high P/E with a very low dividend yield.
Positive Factors
Revenue & profitability growth
Sustained 68% five-year revenue growth and net margin expansion to 9% indicate durable demand and improving operating leverage. Persistent top-line expansion plus rising margins support continued cash generation and reinvestment capacity over the next 2–6 months and beyond.
Negative Factors
EBITDA margins lag peers
Despite profit improvement, EBITDA margins remain below industry leaders, indicating weaker operating efficiency or pricing power. Persistent margin gap could limit competitive flexibility and long-term return potential unless operational scale or mix improvements are achieved.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue & profitability growth
Sustained 68% five-year revenue growth and net margin expansion to 9% indicate durable demand and improving operating leverage. Persistent top-line expansion plus rising margins support continued cash generation and reinvestment capacity over the next 2–6 months and beyond.
Read all positive factors
Artemis Medicare Services Ltd. (ARTEMISMED) vs. iShares MSCI India ETF (INDA)
Market Cap
₹36.07B
Dividend Yield0.16%
Average Volume (3M)16.54K
Price to Earnings (P/E)42.3
Beta (1Y)1.19
Revenue Growth10.27%
EPS Growth45.15%
CountryIN
Employees1,991
SectorHealthcare
Sector Strength45
IndustryMedical - Care Facilities
Share Statistics
EPS (TTM)1.60
Shares Outstanding158,273,650
10 Day Avg. Volume28,644
30 Day Avg. Volume16,535
Financial Highlights & Ratios
PEG Ratio1.06
Price to Book (P/B)5.05
Price to Sales (P/S)4.51
P/FCF Ratio80.55
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)8.7
Revenue Forecast (FY)₹12.91B
Artemis Medicare Services Ltd. Business Overview & Revenue Model
Company Description
Artemis Medicare Services Limited manages and operates multi specialty hospitals in India and internationally. The company offers medical and surgical intervention; and inpatient and outpatient services. It also operates Artemis Hospital, a 541 be...
How the Company Makes Money
ARTEMISMED generates revenue through multiple streams, primarily by billing patients and insurance providers for medical services rendered in its facilities, including surgeries, consultations, and diagnostic tests. Additionally, the company earns...
Artemis Medicare Services Ltd. Financial Statement Overview
Summary
Income Statement
85
Very Positive
Balance Sheet
78
Positive
Cash Flow
80
Positive
| Breakdown | TTM | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 10.02B | 9.37B | 8.79B | 7.37B | 5.53B | 4.08B |
| Gross Profit | 2.27B | 2.23B | 1.78B | 1.04B | 954.40M | 371.67M |
| EBITDA | 1.67B | 1.52B | 1.25B | 1.01B | 713.53M | 359.53M |
| Net Income | 949.45M | 826.26M | 491.41M | 385.98M | 318.14M | 64.86M |
Balance Sheet | ||||||
| Total Assets | 14.26B | 13.57B | 9.72B | 9.05B | 7.10B | 6.00B |
| Cash, Cash Equivalents and Short-Term Investments | 3.48B | 3.96B | 612.05M | 509.42M | 276.98M | 311.20M |
| Total Debt | 2.79B | 2.90B | 3.20B | 2.86B | 2.01B | 1.47B |
| Total Liabilities | 5.38B | 5.14B | 5.17B | 4.97B | 3.48B | 2.78B |
| Stockholders Equity | 8.83B | 8.38B | 4.48B | 4.03B | 3.59B | 3.20B |
Cash Flow | ||||||
| Free Cash Flow | 136.32M | 524.65M | 363.01M | -337.68M | -573.20M | -162.62M |
| Operating Cash Flow | 804.83M | 1.46B | 1.09B | 1.13B | 515.80M | 182.39M |
| Investing Cash Flow | -681.67M | -3.85B | -891.04M | -1.58B | -1.08B | -378.47M |
| Financing Cash Flow | -270.77M | 2.67B | -41.48M | 521.82M | 528.37M | 271.62M |
Artemis Medicare Services Ltd. Technical Analysis
Neutral
276.20
Price Trends
229.85
Positive
250.69
Negative
246.32
Negative
Market Momentum
-2.38
Negative
52.36
Neutral
88.09
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:ARTEMISMED, the sentiment is Neutral. The current price of 276.2 is above the 20-day moving average (MA) of 224.35, above the 50-day MA of 229.85, and above the 200-day MA of 246.32, indicating a neutral trend. The MACD of -2.38 indicates Negative momentum. The RSI at 52.36 is Neutral, neither overbought nor oversold. The STOCH value of 88.09 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for IN:ARTEMISMED.
Artemis Medicare Services Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
65 Neutral | ₹36.07B | 42.27 | ― | 0.16% | 10.27% | 45.15% | |
65 Neutral | ₹265.21B | 114.01 | ― | ― | 25.74% | 1.41% | |
64 Neutral | ₹39.43B | 25.06 | ― | 0.96% | 6.51% | 18.24% | |
61 Neutral | ₹642.13B | 86.12 | ― | 0.11% | 15.33% | 54.62% | |
61 Neutral | ₹94.87B | 60.35 | ― | 0.21% | 15.41% | 5.93% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | ₹16.31B | 310.39 | ― | 0.59% | 11.49% | -91.65% |
* Healthcare Sector Average
IN:ARTEMISMED
Artemis Medicare Services Ltd.
227.90
-52.90
-18.84%
IN:FORTIS
Fortis Healthcare Ltd.
850.55
201.52
31.05%
IN:INDRAMEDCO
Indraprastha Medical Corporation Limited
430.15
32.36
8.13%
IN:KIMS
Krishna Institute of Medical Sciences Limited
662.80
48.05
7.82%
IN:METROPOLIS
Metropolis Healthcare Ltd.
457.60
57.48
14.37%
IN:SHALBY
Shalby Ltd.
151.00
-37.85
-20.04%
Artemis Medicare Services Ltd. Corporate Events
Artemis Medicare Schedules Mumbai Investor and Analyst Meet for February 25
Feb 19, 2026
Artemis Medicare Services Ltd. has scheduled a physical investor and analyst meeting in Mumbai on February 25, 2026, comprising one-on-one and group interactions with a wide range of domestic institutional investors and advisory firms. The company...
Artemis Medicare Publishes Q3 and 9M FY26 Earnings Call Transcript
Feb 9, 2026
Artemis Medicare Services Ltd. has released the transcript of its earnings conference call for the third quarter and nine-month period of FY26, held on February 3, 2026, where management discussed the company’s operational and financial perf...
Artemis Medicare Board Clears Fundraise of Up to Rs 700 Crore
Feb 2, 2026
Artemis Medicare Services Ltd. has secured board approval to raise up to Rs 700 crore through a mix of equity and debt-linked instruments, including shares, convertible and non-convertible debentures, and warrants, via routes such as preferential ...
Artemis Medicare Services Expands Equity Through Stock Option Plan
Dec 17, 2025
Artemis Medicare Services Ltd. has announced the allotment of 105,750 equity shares as part of its Artemis Medicare Management Stock Option Plan-2021, approved by the Nomination and Remuneration Committee. This move results in an increase in the c...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.